Recent Analysts’ Ratings Updates for United Therapeutics (UTHR)

Several analysts have recently updated their ratings and price targets for United Therapeutics (NASDAQ: UTHR):

• 10/28/2026 – United Therapeutics had its price target lowered by JPMorgan Chase & Co. from $710.00 to $695.00. They now have an “overweight” rating on the stock.
• 10/26/2026 – United Therapeutics had its “overweight” rating reaffirmed by Cantor Fitzgerald. They now have a $850.00 price target on the stock.
• 10/22/2026 – United Therapeutics had its price target lowered by Royal Bank Of Canada from $708.00 to $697.00. They now have an “outperform” rating on the stock.
• 10/20/2026 – United Therapeutics had its “outperform” rating reaffirmed by Raymond James Financial. They now have a $717.00 price target on the stock.
• 10/19/2026 – United Therapeutics was given a new $725.00 price target by UBS Group.
• 10/19/2026 – United Therapeutics had its price target raised by Leerink Partners from $685.00 to $725.00. They now have an “outperform” rating on the stock.
• 10/15/2026 – United Therapeutics had its “sell” rating reaffirmed by The Goldman Sachs Group. They now have a $368.00 price target on the stock.
• 10/14/2026 – United Therapeutics had its “buy” rating reaffirmed by Jefferies Financial Group. They now have a $728.00 price target on the stock.
• 10/8/2026 – United Therapeutics had its price target raised by Royal Bank Of Canada from $677.00 to $708.00. They now have an “outperform” rating on the stock.
• 10/7/2026 – United Therapeutics had its price target raised by Morgan Stanley from $515.00 to $566.00. They now have an “equal weight” rating on the stock.
• 10/1/2026 – United Therapeutics had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 9/24/2026 – United Therapeutics is now covered by The Goldman Sachs Group. They set a “sell” rating and a $321.00 price target on the stock.
• 9/24/2026 – United Therapeutics is now covered by The Goldman Sachs Group. They set a “sell” rating and a $321.00 price target on the stock.

United Therapeutics Trading Up 0.9%

Shares of NASDAQ UTHR opened at $601.32 on Wednesday. United Therapeutics Corporation has a 12 month low of $430.02 and a 12 month high of $609.99. The firm has a market capitalization of $25.79 billion, a PE ratio of 21.51, a price-to-earnings-growth ratio of 4.32 and a beta of 0.49. The firm has a fifty day simple moving average of $530.53 and a two-hundred day simple moving average of $531.77.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, November 4th. The biotechnology company reported $5.71 EPS for the quarter, missing the consensus estimate of $6.01 by ($0.30). The company had revenue of $832.50 million during the quarter, compared to analysts’ expectations of $781.14 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%. The company’s revenue for the quarter was up 4.1% on a year-over-year basis. During the same period in the prior year, the business posted $7.16 earnings per share. On average, sell-side analysts predict that United Therapeutics Corporation will post 26.09 earnings per share for the current year.

Insider Transactions at United Therapeutics

In related news, CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $526.96, for a total value of $5,006,120.00. Following the completion of the transaction, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at $170,968,483.28. This represents a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have sold 401,528 shares of company stock valued at $211,631,836 over the last ninety days. 8.60% of the stock is owned by corporate insiders.

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for patients with life-threatening conditions, particularly pulmonary arterial hypertension (PAH). The company’s portfolio includes Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable treprostinil product; and Orenitram, an oral treprostinil therapy. These treatments are designed to improve exercise ability and delay disease progression in people with PAH.

The company also markets Unituxin, an antibody therapy used as part of treatment for high-risk neuroblastoma, a type of childhood cancer.